Search Results - craig+thomas

9 Results

Sort By:

Anti-Viral Compounds that Inhibit HIV Activity

Abstract: Several novel tropolone derivatives have been identified that inhibit HIV-1 RNase H function and have potential for anti-viral activity due to reduced cellular toxicity. Inhibiting RNase H function is a potential treatment for many viral infections, since RNase H function is essential for viral replication for many pathogenic retroviruses...

Published: 8/6/2025 | Inventor(s): John Beutler, Jiankang Jiang, Suhman Chung, Craig Thomas, Stuart LeGrice, Jennifer Wilson

Keywords(s): AIDS, HIV, ribonuclease H, RNase H, tropolone derivative, viral replication

Category(s): Collaboration Sought > Licensing, Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Infectious Disease

Development and Use of O-linked beta-N-acetylglucosamine (O-GlcNAc) Transferase (OGT) Inhibitors for Multiple Conditions, Including Cancer

This technology includes the development and use of small molecules that inhibit O-linked beta-N-acetylglucosamine (O-GlcNAc) transferase (OGT) for a variety of pathologies, including Alzheimer's disease, cancer, cancer, diabetes, and neurodegenerative disorders the treatment of cancer and as a potential antiviral. OGT is a ubiquitous enzyme that catalyzes...

Published: 10/28/2024 | Inventor(s): Sara Martin Schwanger, Craig Thomas, Damien Duveau, Suzanne Walker

Keywords(s): 0-GlcNAc, Development, Developmtent, Inhibitors, OGT, THEREOF, TRANSFERASE, USES, VEXXXX, WIXXXX, WKXXXX

Category(s): Application > Research Materials, TherapeuticArea > Neurology, Application > Therapeutics

Treatment of Acute Myeloid Leukemia (AML) with the Multi-kinase FLT3-IRAK1/4 Inhibitor, NCGC1481, to Avoid Adaptive Resistance

This technology includes the identification and use of a novel small molecule, NCGC1481, to inhibit both the FLT3 and IRAK1/4 kinase pathways for treating acute myeloid leukemia (AML). An activating mutation of the FMS-like receptor kinase 3 (FMT3) occurs in approximately 25% of AML cases. Consequently, FLT3 inhibitors (FLT3i) have a good initial clinical...

Published: 10/28/2024 | Inventor(s): Jian-kang Jiang, Craig Thomas

Keywords(s): FTL3/IRAK, Inhibitors, MOLECULE, Small, VCXXXX, WIXXXX, WKXXXX, XEXXXX

Category(s): Application > Therapeutics, TherapeuticArea > Oncology, Application > Research Materials

Discovery of imidazo[1,2-b]pyridazines with Anticancer Properties

This technology includes a series of imidazo[1,2-b]pyridazines that display potent inhibition of FLT3, as well as potent binding and activity against FLT3 tyrosine kinase domain and gatekeeper mutations. This chemotype exhibits superior anti-leukemic activity against the common clinically-relevant FLT3-mutant acute myeloid leukemia (AML) in vitro and...

Published: 10/28/2024 | Inventor(s): Scott Hoyt, Patrick Sutter, Chris Finocchio, Daniel Starczynowski, Gregory Tawa, Craig Thomas

Keywords(s): 2-b]pyridazines, ANTICANCER, Discovery, Imidazo[1, PROPERTIES, VCXXXX, WIXXXX, WKXXXX

Category(s): Application > Therapeutics, Application > Research Materials, TherapeuticArea > Oncology

Use of the Ketamine Metabolite (R,6R)-hydroxynorketamine in Depression

This technology includes the identification and use of a ketamine metabolite, (2R,6R)-2-amino-2-(2-chlorophenyl)-6-hydroxycyclohexanone (HNK), for the treatment of depression. Ketamine is an NMDA receptor antagonist that exerts a rapid and sustained antidepressant and anti-suicidal effect. However, even low doses of ketamine has addictive and psychomimetic...

Published: 4/23/2025 | Inventor(s): Todd Gould, Irving Wainer, Carlos Zarate, Ruin Moaddel, Patrick Morris, Panos Zanos, Craig Thomas

Keywords(s): 2R, 6R-hydroxynorketamine, depression, Ketamine, METABOLITE, VEXXXX, VNXXXX, WIXXXX, WKXXXX

Category(s): TherapeuticArea > Neurology, TherapeuticArea > Psychiatry/Mental Health, Application > Therapeutics, Application > Research Materials

Pyruvate Kinase M2 Activators for the Treatment of Cancer

This technology describes a series of small-molecule activators of the pyruvate kinase M2 isoform (PK-M2). Pyruvate kinase (PK) is a critical metabolic enzyme that catalyzes the last step of the glycolytic pathway. It exists in several isoforms with different patterns of tissue expression. One isoform, PK-M2, is expressed in cells with a high rate...

Published: 11/5/2024 | Inventor(s): Jian-kang Jiang, Matthew Boxer, Min Shen, Douglas Auld, Craig Thomas

Keywords(s): Activator, ACTIVATORS, CANCER, CBXXXX, CXXXXX, Dimer, IBXXXX, ISOFORM, IXXXXX, M2, METABOLIC, METABOLITE, PK, PKM2, PK-M2, Proliferation, PYRUVATE, pyruvate kinase, small molecule, Tetramer, tumor

Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Oncology, Application > Diagnostics, Application > Research Materials

Pyruvate Kinase M2 Activators for the Treatment of Cancer

NIH investigators have discovered a series of small compounds with the potential to treat a variety of cancers as well as hemolytic anemia. Contrary to most cancer medications, these molecules can be non-toxic to normal cells because they target a protein specific to the metabolic pathways in tumors, thus representing a significant clinical advantage...

Published: 8/13/2025 | Inventor(s): Min Shen, Craig Thomas, Douglas Auld, Matthew Boxer

Keywords(s): [1, [b], 2, 2-oxo-1, 3, 3-oxo-3, 4], 4-dihydroquinoline-2H-benzo, 4-tetrahydroquinoline-6-sulfonamides, ACTIVATORS, CB3CXX, CB3XXX, CBXXXX, CXXXXX, Human, Kinase, MOLECULE, Oxazine-7-sulfonamides, Patent Category - Chemistry, PYRUVATE, Small, Substituted

Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Oncology

Caspase Inhibitors Useful for the Study of Autoimmune or Inflammatory Diseases

Novel and potent caspase 1 inhibitors are available for licensing. In particular, this technology discloses potent and selective caspase 1 inhibitors that target the active site of the enzyme. Caspase 1 is known to play a pro-inflammatory role in numerous autoimmune and inflammatory diseases and therefore represents an excellent target for treatment...

Published: 8/13/2025 | Inventor(s): Matthew Boxer, Craig Thomas

Keywords(s): 1, Amyotrophic lateral sclerosis, Amyotrophic lateral sclerosis 1; Amyotrophic lateral scleros, Amyotrophic lateral sclerosis 6, Caspase, IB3XXX, IBXXXX, Inflammatory bowel disease 1, inhibitor, IXXXXX, Lou Gehrig's disease, Patent Category - Chemistry

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Diagnostics, Application > Research Materials, Application > Therapeutics, TherapeuticArea > Immunology

Small Molecule Activators of Human Pyruvate Kinase for Treatment of Cancer and Enzyme-Deficient Hemolytic Anemia

Published: 8/13/2025 | Inventor(s): Craig Thomas

Keywords(s): 3-@hydroxyacyl-coa dehydrogenase deficiency, ACTIVATORS, CB3CXX, CB3XXX, CBXXXX, CXXXXX, HAD deficiency, HIS deficiency, Histidinemia, Human, Kinase, MOLECULE, Patent Category - Chemistry, PYRUVATE, Small

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology